

(1-187)

1. Yao R, Natsume Y, Saiki Y, Shioya H, Takeuchi K, Yamori T, Toki H, Aoki I, Saga T, Noda T. Disruption of Tacc3 function leads to in vivo tumor regression. *Oncogene*. 2012;31(2):135-148.
2. Ushijima M, Mashima T, Tomida A, Dan S, Saito S, Furuno A, Tsukahara S, Seimiya H, Yamori T, Matsuura M. Development of a gene expression database and related analysis programs for evaluation of anticancer compounds. *Cancer Sci*. 2012;
3. Shiina I, Umezaki Y, Ohashi Y, Yamazaki Y, Dan S, Yamori T. Total Synthesis and Anticancer Activity of AMF-26 Targeting ADP-ribosylation Factor 1 (Arf1). *J Med Chem*. 2012;
4. Ohashi Y, Iijima H, Yamaotsu N, Yamazaki K, Sato S, Okamura M, Sugimoto K, Dan S, Hirono S, Yamori T. AMF-26, a Novel Inhibitor of the Golgi System, Targeting ADP-ribosylation Factor 1 (Arf1) with Potential for Cancer Therapy. *J Biol Chem*. 2012;287(6):3885-3897.
5. Morita M, Ohno O, Teruya T, Yamori T, Inuzuka T, Suenaga K. Isolation and structures of biselyngbyasides B, C, and D from the marine cyanobacterium *Lyngbya* sp., and the biological activities of biselyngbyasides. *Tetrahedron*. 2012;68(29):5984-5990.
6. Miyazaki T, Pan Y, Joshi K, Purohit D, Hu B, Demir H, Mazumder S, Okabe S, Yamori T, Viapiano M, Shin-Ya K, Seimiya H, Nakano I. Telomestatin Impairs Glioma Stem Cell Survival and Growth through the Disruption of Telomeric G-Quadruplex and Inhibition of the Proto-oncogene, c-Myb. *Clin Cancer Res*. 2012;18(5):1268-1280.
7. Kong D, Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. *Bioorg Med Chem*. 2012;20(6):1947-1951.
8. Kimura KI, Sakamoto Y, Fujisawa N, Uesugi S, Aburai N, Kawada M, Ohba SI, Yamori T, Tsuchiya E, Koshino H. Cleavage mechanism and anti-tumor activity of 3,6-epidioxy-1,10-bisaboladiene isolated from edible wild plants. *Bioorg Med Chem*. 2012;20(12):3887-3897.
9. Kaneko M, Matsuda D, Ohtawa M, Fukuda T, Nagamitsu T, Yamori T, Tomoda H. Potentiation of bleomycin in jurkat cells by fungal pycnidione. *Biol Pharm Bull*. 2012;35(1):18-28.
10. Isoyama S, Yoshimi H, Dan S, Okamura M, Seki M, Irimura T, Yamori T. Development of an immunohistochemical protein quantification system in conjunction with tissue microarray technology for identifying predictive biomarkers for phosphatidylinositol 3-kinase inhibitors. *Biol Pharm Bull*. 2012;35(9):1607-1613.
11. Isoyama S, Dan S, Nishimura Y, Nakamura N, Kajiwara G, Seki M, Irimura T,

Yamori T. Establishment of phosphatidylinositol 3-kinase inhibitor-resistant cancer cell lines and therapeutic strategies for overcoming the resistance. *Cancer Sci.* 2012;103(11):1955-1960.

12. Haruta K, Mori S, Tamura N, Sasaki A, Nagamine M, Yaguchi S, Kamachi F, Enami J, Kobayashi S, Yamori T, Takasaki Y. Inhibitory effects of ZSTK474, a phosphatidylinositol 3-kinase inhibitor, on adjuvant-induced arthritis in rats. *Inflamm Res.* 2012;61(6):551-562.

13. Dan S, Okamura M, Mukai Y, Yoshimi H, Inoue Y, Hanyu A, Sakaue-Sawano A, Imamura T, Miyawaki A, Yamori T. ZSTK474, a specific phosphatidylinositol 3-kinase inhibitor, induces G1 arrest of the cell cycle in vivo. *Eur J Cancer.* 2012;48(6):936-943.

14. Murakami M, Cabral H, Matsumoto Y, Wu S, Kano MR, Yamori T, Nishiyama N, Kataoka K. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting. *Sci Transl Med.* 2011;3(64):64ra62.

15. Kong D, Zhang Y, Yamori T, Duan H, Jin M. Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms. *Molecules.* 2011;16(6):5159-5167.

16. Kong D, Yamori T, Kobayashi M, Duan H. Antiproliferative and antiangiogenic activities of smenospongine, a marine sponge sesquiterpene aminoquinone. *Mar Drugs.* 2011;9(2):154-161.

17. Kojima N, Suga Y, Hayashi H, Yamori T, Yoshimitsu T, Tanaka T. Design and synthesis of C35-fluorinated solamins and their growth inhibitory activities against human cancer cell lines. *Bioorg Med Chem Lett.* 2011;21(19):5745-5749.

18. Fuwa H, Suzuki T, Kubo H, Yamori T, Sasaki M. Total synthesis and biological assessment of (-)-exiguolide and analogues. *Chemistry.* 2011;17(9):2678-2688.

19. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. *Clin Cancer Res.* 2011;17(8):2260-2269.

20. Awale S, Linn TZ, Li F, Tezuka Y, Myint A, Tomida A, Yamori T, Esumi H, Kadota S. Identification of chrysopenetin from *Vitex negundo* as a potential cytotoxic agent against PANC-1 and a panel of 39 human cancer cell lines (JFCR-39). *Phytother Res.* 2011;25(12):1770-1775.

21. Anzai K, Sekine-Suzuki E, Ueno M, Okamura M, Yoshimi H, Dan S, Yaguchi S, Enami J, Yamori T, Okayasu R. Effectiveness of combined treatment using X-rays and a phosphoinositide 3-kinase inhibitor, ZSTK474, on proliferation of HeLa cells in vitro and in vivo. *Cancer Sci.* 2011;102(6):1176-1180.

22. Yokosuka A, Sato K, Yamori T, Mimaki Y. Triterpene glycosides from *Curculigo*

orchioides and their cytotoxic activity. *J Nat Prod.* 2010;73(6):1102-1106.

23. Ueoka R, Ise Y, Ohtsuka S, Okada S, Yamori T, Matsunaga S. Yaku'amides A and B, cytotoxic linear peptides rich in dehydroamino acids from the marine sponge *Ceratopsion* sp. *J Am Chem Soc.* 2010;132(50):17692-17694.

24. Toyama S, Tamura N, Haruta K, Karakida T, Mori S, Watanabe T, Yamori T, Takasaki Y. Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice. *Arthritis Res Ther.* 2010;12(3):R92.

25. Momose I, Ohba S, Tatsuda D, Kawada M, Masuda T, Tsujiuchi G, Yamori T, Esumi H, Ikeda D. Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions. *Biochem Biophys Res Commun.* 2010;392(3):460-466.

26. Laroche-Clary A, Le Morvan V, Yamori T, Robert J. Cytochrome P450 1B1 gene polymorphisms as predictors of anticancer drug activity: studies with in vitro models. *Mol Cancer Ther.* 2010;9(12):3315-3321.

27. Koyama J, Morita I, Yamori T. Correlation between cytotoxic activities and reduction potentials of heterocyclic quinones. *Molecules.* 2010;15(9):6559-6569.

28. Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery system. *Acta Pharmacol Sin.* 2010;31(9):1189-1197.

29. Kong D, Yamazaki K, Yamori T. Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the Screening Committee of Anticancer Drugs (SCADS) library. *Biol Pharm Bull.* 2010;33(9):1600-1604.

30. Kong D, Dan S, Yamazaki K, Yamori T. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. *Eur J Cancer.* 2010;46(6):1111-1121.

31. Kojima N, Morioka T, Urabe D, Yano M, Suga Y, Maezaki N, Ohashi-Kobayashi A, Fujimoto Y, Maeda M, Yamori T, Yoshimitsu T, Tanaka T. Convergent synthesis of fluorescence-labeled probes of Annonaceous acetogenins and visualization of their cell distribution. *Bioorg Med Chem.* 2010;18(24):8630-8641.

32. Ihara Y, Kihara Y, Hamano F, Yanagida K, Morishita Y, Kunita A, Yamori T, Fukayama M, Aburatani H, Shimizu T, Ishii S. The G protein-coupled receptor T-cell death-associated gene 8 (TDAG8) facilitates tumor development by serving as an extracellular pH sensor. *Proc Natl Acad Sci U S A.* 2010;107(40):17309-17314.

33. Hiramatsu M, Ninomiya H, Inamura K, Nomura K, Takeuchi K, Satoh Y, Okumura S, Nakagawa K, Yamori T, Matsuura M, Morikawa T, Ishikawa Y. Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with

reference of KRAS and EGFR mutations. *Lung Cancer*. 2010;70(1):94-102.

34. Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations. *Cancer Res*. 2010;70(12):4982-4994.

35. Chou LC, Chen CT, Lee JC, Way TD, Huang CH, Huang SM, Teng CM, Yamori T, Wu TS, Sun CM, Chien DS, Qian K, Morris-Natschke SL, Lee KH, Huang LJ, Kuo SC. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. *J Med Chem*. 2010;53(4):1616-1626.

36. Takahata M, Inoue Y, Tsuda H, Imoto I, Koinuma D, Hayashi M, Ichikura T, Yamori T, Nagasaki K, Yoshida M, Matsuoka M, Morishita K, Yuki K, Hanyu A, Miyazawa K, Inazawa J, Miyazono K, Imamura T. SKI and MEL1 cooperate to inhibit transforming growth factor-beta signal in gastric cancer cells. *J Biol Chem*. 2009;284(5):3334-3344.

37. Suzuki N, Suzuki T, Ota Y, Nakano T, Kurihara M, Okuda H, Yamori T, Tsumoto H, Nakagawa H, Miyata N. Design, synthesis, and biological activity of boronic acid-based histone deacetylase inhibitors. *J Med Chem*. 2009;52(9):2909-2922.

38. Nomura T, Uehara Y, Kawajiri H, Ryoyama K, Yamori T, Fuke Y. Alkyl isothiocyanates suppress epidermal growth factor receptor kinase activity but augment tyrosine kinase activity. *Cancer Epidemiol*. 2009;33(3-4):288-292.

39. Narita K, Kikuchi T, Watanabe K, Takizawa T, Oguchi T, Kudo K, Matsuhara K, Abe H, Yamori T, Yoshida M, Katoh T. Total Synthesis of the Bicyclic Depsipeptide HDAC Inhibitors Spiruchostatins A and B, 5''-epi-Spiruchostatin B, FK228 (FR901228) and Preliminary Evaluation of Their Biological Activity. *Chemistry*. 2009;15(42):11174-11186.

40. Nakamura T, Nakatsu N, Yoshida Y, Yamazaki K, Dan S, Sadahiro S, Makuuchi H, Yamori T. Identification of candidate genes determining chemosensitivity to anti-cancer drugs of gastric cancer cell lines. *Biol Pharm Bull*. 2009;32(11):1936-1939.

41. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. *Curr Med Chem*. 2009;16(22):2839-2854.

42. Kong D, Yaguchi S, Yamori T. Effect of ZSTK474, a Novel Phosphatidylinositol 3-Kinase Inhibitor, on DNA-Dependent Protein Kinase. *Biol Pharm Bull*. 2009;32(2):297-300.

43. Kong D, Okamura M, Yoshimi H, Yamori T. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor. *Eur J Cancer*. 2009;45(5):857-865.

44. Faur N, Araud L, Laroche-Clary A, Kanno J, Toutain J, Yamori T, Robert J, Le Morvan V. The association between the T309G polymorphism of the MDM2 gene and

sensitivity to anticancer drug is dependent on the p53 mutational status in cellular models. *Br J Cancer*. 2009;101(2):350-356.

45. Dan S, Yoshimi H, Okamura M, Mukai Y, Yamori T. Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest. *Biochem Biophys Res Commun*. 2009;379(1):104-109.

46. Akashi T, Yamori T. Proteomic analysis of phosphoproteins sensitive to a phosphatidylinositol 3-kinase inhibitor, ZSTK474, by using SELDI-TOF MS. *Proteome Sci*. 2009;7:14.

47. Wang L, Bai L, Tokunaga D, Watanabe Y, Hasegawa T, Sakai J, Tang W, Bai Y, Hirose K, Yamori T, Tomida A, Tsuruo T, Ando M. The polar neutral and basic taxoids isolated from needles and twigs of *Taxus cuspidata* and their biological activity. *J Wood Sci*. 2008;54(6):390-401.

48. Sugita H, Dan S, Kong D, Tomida A, Yamori T. A new evaluation method for quantifying PI3K activity by HTRF assay. *Biochem Biophys Res Commun*. 2008;377(3):941-945.

49. Shiina I, Sano Y, Nakata K, Kikuchi T, Sasaki A, Ikekita M, Nagahara Y, Hasome Y, Yamori T, Yamazaki K. Synthesis and pharmacological evaluation of the novel pseudo-symmetrical tamoxifen derivatives as anti-tumor agents. *Biochem Pharmacol*. 2008;75(5):1014-1026.

50. Saito H, Minamisawa T, Yamori T, Shiba K. Motif-programmed artificial protein induces apoptosis in several cancer cells by disrupting mitochondria. *Cancer Sci*. 2008;99(2):398-406.

51. Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. *Cancer Sci*. 2008;99(9):1734-1740.

52. Kojima N, Hayashi H, Suzuki S, Tominaga H, Maezaki N, Tanaka T, Yamori T. Synthesis of C4-fluorinated solamins and their growth inhibitory activity against human cancer cell lines. *Bioorg Med Chem Lett*. 2008;18(24):6451-6453.

53. Kojima N, Fushimi T, Maezaki N, Tanaka T, Yamori T. Synthesis of hybrid acetogenins, alpha,beta-unsaturated-gamma-lactone-free nitrogen-containing heterocyclic analogues, and their cytotoxicity against human cancer cell lines. *Bioorg Med Chem Lett*. 2008;18(5):1637-1641.

54. Chen CJ, Hsu MH, Huang LJ, Yamori T, Chung JG, Lee FY, Teng CM, Kuo SC. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. *Biochem Pharmacol*. 2008;75(2):360-368.

55. Yokosuka A, Haraguchi M, Usui T, Kazami S, Osada H, Yamori T, Mimaki Y. Glaziopianin A, a new isoflavone, from the leaves of *Ateleia glaziouviana* and its cytotoxic

- activity against human cancer cells. *Bioorg Med Chem Lett*. 2007;17(11):3091-3094.
56. Yamaguchi T, Yoshida T, Kurachi R, Kakegawa J, Hori Y, Nanayama T, Hayakawa K, Abe H, Takagi K, Matsuzaki Y, Koyama M, Yogosawa S, Sowa Y, Yamori T, Tajima N, Sakai T. Identification of JTP-70902, a p15(INK4b)-inductive compound, as a novel MEK1/2 inhibitor. *Cancer Sci*. 2007;98(11):1809-1816.
57. Nakatsu N, Nakamura T, Yamazaki K, Sadahiro S, Makuuchi H, Kanno J, Yamori T. Evaluation of Action Mechanisms of Toxic Chemicals Using JFCR39, a Panel of Human Cancer Cell Lines. *Mol Pharmacol*. 2007;72(5):1171-1180.
58. Nakamura H, Dan S, Akashi T, Unno M, Yamori T. Absolute quantification of four isoforms of the class I phosphoinositide-3-kinase catalytic subunit by real-time RT-PCR. *Biol Pharm Bull*. 2007;30(6):1181-1184.
59. Matsuoka A, Isama K, Tanimura S, Kohno M, Yamori T. A novel candidate compound with urethane structure for anticancer drug development. *Curr Drug Discov Technol*. 2007;4(2):69-76.
60. Matsuo Y, Kanoh K, Yamori T, Kasai H, Katsuta A, Adachi K, Shin-Ya K, Shizuri Y. Urukthapelstatin A, a novel cytotoxic substance from marine-derived *Mechercharimyces asporophorigenens* YM11-542. I. Fermentation, isolation and biological activities. *J Antibiot (Tokyo)*. 2007;60(4):251-255.
61. Kuroda M, Yokosuka A, Kobayashi R, Jitsuno M, Kando H, Nosaka K, Ishii H, Yamori T, Mimaki Y. Sesquiterpenoids and flavonoids from the aerial parts of *Tithonia diversifolia* and their cytotoxic activity. *Chem Pharm Bull (Tokyo)*. 2007;55(8):1240-1244.
62. Kong D, Yamori T. ZSTK474 is an ATP-competitive inhibitor of class I phosphatidylinositol 3 kinase isoforms. *Cancer Sci*. 2007;98(10):1638-1642.
63. Ito H, Iwasaki J, Sato Y, Aoyagi M, Iguchi K, Yamori T. Marine diterpenoids with a briarane skeleton from the Okinawan soft coral *Pachyclavularia violacea*. *Chem Pharm Bull (Tokyo)*. 2007;55(12):1671-1676.
64. Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. *Biol Pharm Bull*. 2007;30(9):1779-1783.
65. Inoue A, Seino Y, Terasaka S, Hayashi S, Yamori T, Tanji M, Kiyama R. Comparative profiling of the gene expression for estrogen responsiveness in cultured human cell lines. *Toxicol In Vitro*. 2007;21(4):741-752.
66. Ichikawa K, Sakabe E, Kuninobu K, Yamori T, Tsuruo T, Yao T, Tsuneyoshi M, Utsumi H. Application of in vivo ESR/spin-probe technique to monitor tumor in vivo in mouse footpad. *Antioxid Redox Signal*. 2007;9(10):1699-1707.
67. Hasegawa T, Bai J, Dai J, Bai L, Sakai J, Nishizawa S, Bai Y, Kikuchi M, Abe M,

Yamori T, Tomida A, Tsuruo T, Hirose K, Ando M. Synthesis and structure-activity relationships of taxuyunnanine C derivatives as multidrug resistance modulator in MDR cancer cells. *Bioorg Med Chem Lett*. 2007;17(13):3722-3728.

68. Araki H, Inoue M, Suzuki T, Yamori T, Kohno M, Watanabe K, Abe H, Katoh T. Enantioselective Total Synthesis of (+)-Ottelione A, (-)-Ottelione B, (+)-3-epi-Ottelione A and Preliminary Evaluation of Their Antitumor Activity. *Chemistry*. 2007;13(35):9866-9881.

69. Amagata T, Tanaka M, Yamada T, Doi M, Minoura K, Ohishi H, Yamori T, Numata A. Variation in cytostatic constituents of a sponge-derived *Gymnascella dankaliensis* by manipulating the carbon source. *J Nat Prod*. 2007;70(11):1731-1740.

70. Akashi T, Yamori T. A novel method for analyzing phosphoproteins using SELDI-TOF MS in combination with a series of recombinant proteins. *Proteomics*. 2007;7(14):2350-2354.

71. Akashi T, Nishimura Y, Wakatabe R, Shiwa M, Yamori T. Proteomics-based identification of biomarkers for predicting sensitivity to a PI3-kinase inhibitor in cancer. *Biochem Biophys Res Commun*. 2007;352(2):514-521.

72. Yaguchi S, Fukui Y, Koshimizu I, Yoshimi H, Matsuno T, Gouda H, Hirono S, Yamazaki K, Yamori T. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. *J Natl Cancer Inst*. 2006;98(8):545-556.

73. Tanaka R, Wada S, Yamada T, Yamori T. Potent antitumor activity of 3,4-seco-8betaH-Ferna-4(23),9(11)-dien-3-oic acid (EC-2) and 3,4-seco-Oleana-4(23),18-dien-3-oic acid (EC-4), evaluated by an in vitro human cancer cell line panel. *Planta Med*. 2006;72(14):1347-1349.

74. Nakamura H, Kuroda H, Saito H, Suzuki R, Yamori T, Maruyama K, Haga T. Synthesis and biological evaluation of boronic acid containing cis-stilbenes as apoptotic tubulin polymerization inhibitors. *ChemMedChem*. 2006;1(7):729-740.

75. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, Yamori T, Aoki J, Fujimaki T, Arai H. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. *J Biol Chem*. 2006;281(25):17492-17500.

76. Kimura H, Katoh T, Kajimoto T, Node M, Hisaki M, Sugimoto Y, Majima T, Uehara Y, Yamori T. Modification of pyrimidine derivatives from antiviral agents to antitumor agents. *Anticancer Res*. 2006;26(1A):91-97.

77. Yoneyama H, Hara T, Kato Y, Yamori T, Matsuura ET, Koike K. Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. *Mol Cancer Res*. 2005;3(1):14-20.

78. Yanagihara M, Sasaki-Takahashi N, Sugahara T, Yamamoto S, Shinomi M,

Yamashita I, Hayashida M, Yamanoha B, Numata A, Yamori T, Andoh T. Leptosins isolated from marine fungus *Leptoshaeria* species inhibit DNA topoisomerases I and/or II and induce apoptosis by inactivation of Akt/protein kinase B. *Cancer Sci.* 2005;96(11):816-824.

79. Sohda KY, Nagai K, Yamori T, Suzuki K, Tanaka A. YM-216391, a novel cytotoxic cyclic peptide from *Streptomyces nobilis*. I. fermentation, isolation and biological activities. *J Antibiot (Tokyo)*. 2005;58(1):27-31.

80. Nomura T, Shinoda S, Yamori T, Sawaki S, Nagata I, Ryoyama K, Fuke Y. Selective sensitivity to wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate of human breast cancer and melanoma cell lines studied in vitro. *Cancer Detect Prev.* 2005;29(2):155-160.

81. Nakatsu N, Yoshida Y, Yamazaki K, Nakamura T, Dan S, Fukui Y, Yamori T. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. *Mol Cancer Ther.* 2005;4(3):399-412.

82. Mashima T, Oh-hara T, Sato S, Mochizuki M, Sugimoto Y, Yamazaki K, Hamada J, Tada M, Moriuchi T, Ishikawa Y, Kato Y, Tomoda H, Yamori T, Tsuruo T. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. *J Natl Cancer Inst.* 2005;97(10):765-777.

83. Maezaki N, Tominaga H, Kojima N, Yanai M, Urabe D, Ueki R, Tanaka T, Yamori T. Total Synthesis of Murisolin and Evaluation of Tumor-Growth Inhibitory Activity. *Chemistry.* 2005;11(21):6237-6245.

84. Lai YY, Huang LJ, Lee KH, Xiao Z, Bastow KF, Yamori T, Kuo SC. Synthesis and biological relationships of 3',6-substituted 2-phenyl-4-quinolone-3-carboxylic acid derivatives as antimitotic agents. *Bioorg Med Chem.* 2005;13(1):265-275.

85. Kamata K, Kiyota M, Naoe A, Nakatani S, Yamamoto Y, Hayashi M, Komiyama K, Yamori T, Ishibashi M. New bisindole alkaloids isolated from Myxomycetes *Arcyria cinerea* and *Lycogala epidendrum*. *Chem Pharm Bull (Tokyo)*. 2005;53(5):594-597.

86. Honma Y, Kasukabe T, Yamori T, Kato N, Sassa T. Antitumor effect of cotylenin A plus interferon-alpha: Possible therapeutic agents against ovary carcinoma. *Gynecol Oncol.* 2005;99(3):680-688.

87. Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H, Tanaka Y, Washida M, Morikane K, Fukushima Y, Yamori T, Tsuruo T, Kawabe T, Miyagishi M, Taira K, Sata M, Omata M. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. *Cancer Res.* 2005;65(13):5864-5871.

88. Tanaka R, Wada S, Aoki H, Matsunaga S, Yamori T. Spiromarienols A and B: two new 7(8 → 9)abeo lanostane-type triterpene lactones from the stem bark of *Abies mariesii*.

Helvetica Chemica Acta. 2004;87(1):240-249.

89. Sakai K, Fukuda Y, Matsunaga S, Tanaka R, Yamori T. New Cytotoxic Oleanane-Type Triterpenoids from the Cones of *Liquidamber styraciflua*. *J Nat Prod.* 2004;67(7):1088-1093.
90. Saito H, Honma T, Minamisawa T, Yamazaki K, Noda T, Yamori T, Shiba K. Synthesis of functional proteins by mixing peptide motifs. *Chem Biol.* 2004;11(6):765-773.
91. Rengifo-Cam W, Konishi A, Morishita N, Matsuoka H, Yamori T, Nada S, Okada M. Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis. *Oncogene.* 2004;23(1):289-297.
92. Park HR, Tomida A, Sato S, Tsukumo Y, Yun J, Yamori T, Hayakawa Y, Tsuruo T, Shin-ya K. Effect on tumor cells of blocking survival response to glucose deprivation. *J Natl Cancer Inst.* 2004;96(17):1300-1310.
93. Mizui Y, Sakai T, Iwata M, Uenaka T, Okamoto K, Shimizu H, Yamori T, Yoshimatsu K, Asada M. Pladienolides, new substances from culture of *Streptomyces platensis* Mer-11107. III. In vitro and in vivo antitumor activities. *J Antibiot (Tokyo).* 2004;57(3):188-196.
94. Mimaki Y, Yokosuka A, Hamanaka M, Sakuma C, Yamori T, Sashida Y. Triterpene Saponins from the Roots of *Clematis chinensis*. *J Nat Prod.* 2004;67(9):1511-1516.
95. Komuro A, Imamura T, Saitoh M, Yoshida Y, Yamori T, Miyazono K, Miyazawa K. Negative regulation of transforming growth factor-beta (TGF-beta) signaling by WW domain-containing protein 1 (WWP1). *Oncogene.* 2004;23(41):6914-6923.
96. Hama K, Aoki J, Fukaya M, Kishi Y, Sakai T, Suzuki R, Ohta H, Yamori T, Watanabe M, Chun J, Arai H. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1. *J Biol Chem.* 2004;279(17):17634-17639.
97. Bai J, Kitabatake M, Toyozumi K, Fu L, Zhang S, Dai J, Sakai J, Hirose K, Yamori T, Tomida A, Tsuruo T, Ando M. Production of Biologically Active Taxoids by a Callus Culture of *Taxus cuspidata*. *J Nat Prod.* 2004;67(1):58-63.
98. Yang L, Mashima T, Sato S, Mochizuki M, Sakamoto H, Yamori T, Oh-Hara T, Tsuruo T. Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. *Cancer Res.* 2003;63(4):831-837.
99. Yamori T. Panel of human cancer cell lines provides valuable database for drug discovery and bioinformatics. *Cancer Chemother Pharmacol.* 2003;52 Suppl 1:74-79.
100. Umemura K, Yanase K, Suzuki M, Okutani K, Yamori T, Andoh T. Inhibition of DNA topoisomerases I and II, and growth inhibition of human cancer cell lines by a marine

microalgal polysaccharide. *Biochem Pharmacol.* 2003;66(3):481-487.

101. Tanabe M, Izumi H, Ise T, Higuchi S, Yamori T, Yasumoto K, Kohno K. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. *Cancer Res.* 2003;63(24):8592-8595.

102. Suzuki M, Watanabe K, Fujiwara S, Kurasawa T, Wakabayashi T, Tsuzuki M, Iguchi K, Yamori T. Isolation of Peridinin-Related Norcarotenoids with Cell Growth-Inhibitory Activity from the Cultured Dinoflagellate of *Symbiodinium* sp., a Symbiont of the Okinawan Soft Coral *Clavularia viridis*, and Analysis of Fatty Acids of the Dinoflagellate. *Chem Pharm Bull (Tokyo).* 2003;51(6):724-727.

103. Sugiyama Y, Dan S, Yoshida Y, Akiyama F, Sugiyama K, Hirai Y, Matsuura M, Miyata S, Ushijima M, Hasumi K, Yamori T. A large-scale gene expression comparison of microdissected, small-sized endometrial cancers with or without hyperplasia matched to same-patient normal tissue. *Clin Cancer Res.* 2003;9(15):5589-5600.

104. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. *Biochem Biophys Res Commun.* 2003;309(1):18-25.

105. Matsuda M, Yamori T, Naitoh M, Okutani K. Structural revision of sulfated polysaccharide B-1 isolated from a marine *Pseudomonas* species and its cytotoxic activity against human cancer cell lines. *Mar Biotechnol (NY).* 2003;5(1):13-19.

106. Mashino T, Nishikawa D, Takahashi K, Usui N, Yamori T, Seki M, Endo T, Mochizuki M. Antibacterial and antiproliferative activity of cationic fullerene derivatives. *Bioorg Med Chem Lett.* 2003;13(24):4395-4397.

107. Dan S, Shirakawa M, Mukai Y, Yoshida Y, Yamazaki K, Kawaguchi T, Matsuura M, Nakamura Y, Yamori T. Identification of candidate predictive markers of anticancer drug sensitivity using a panel of human cancer cell lines. *Cancer Sci.* 2003;94(12):1074-1082.

108. Bando T, Iida H, Tao ZF, Narita A, Fukuda N, Yamori T, Sugiyama H. Sequence specificity, reactivity, and antitumor activity of DNA-alkylating pyrrole-imidazole diamides. *Chem Biol.* 2003;10(8):751-758.

109. Andoh T, Umemura K, Yanase K, Yamori T. Development of new topoisomerase II-targeting compounds as candidate anticancer drugs. New York: Kluwer Academic/Plenum Publishers; 2003.

110. Yamada T, Iwamoto C, Yamagaki N, Yamanouchi T, Minoura K, Yamori T, Uehara Y, Toshiwo A, Umemura K, Numata A. Leptosins M-N₁, cytotoxic metabolites from a *Leptosphaeria* species separated from a marine alga. Structure determination and biological activities. *Tetrahedron.* 2002;58:479-487.

111. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J, Arai H. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. *J Cell Biol.* 2002;158(2):227-233.
112. Umemura K, Mizushima T, Katayama H, Kiryu Y, Yamori T, Andoh T. Inhibition of DNA topoisomerases II and/or I by pyrazolo[1,5-a]indole derivatives and their growth inhibitory activities. *Mol Pharmacol.* 2002;62(4):873-880.
113. Uesato S, Kitagawa M, Nagaoka Y, Maeda T, Kuwajima H, Yamori T. Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. *Bioorg Med Chem Lett.* 2002;12(10):1347-1349.
114. Sawada M, Moriya S, Saito S, Shineha R, Satomi S, Yamori T, Tsuruo T, Kannagi R, Miyagi T. Reduced sialidase expression in highly metastatic variants of mouse colon adenocarcinoma 26 and retardation of their metastatic ability by sialidase overexpression. *Int J Cancer.* 2002;97(2):180-185.
115. Sasaki T, Yamazaki K, Yamori T, Endo T. Inhibition of proliferation and induction of differentiation of glioma cells with *Datura stramonium* agglutinin. *Br J Cancer.* 2002;87(8):918-923.
116. Owa T, Yokoi A, Yamazaki K, Yoshimatsu K, Yamori T, Nagasu T. Array-Based Structure and Gene Expression Relationship Study of Antitumor Sulfonamides Including N-[2-[(4-Hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-Chloro-7-indolyl)-1,4-benzenedisulfonamide. *J Med Chem.* 2002;45(22):4913-4922.
117. Naasani I, Yamori T, Tsuruo T. Screening with COMPARE analysis for telomerase inhibitors. *Methods Mol Biol.* 2002;191:197-207.
118. Iwashima M, Terada I, Iguchi K, Yamori T. New biologically active marine sesquiterpenoid and steroid from the okinawan sponge of the genus *axinyssa*. *Chem Pharm Bull (Tokyo).* 2002;50(9):1286-1289.
119. Iwashima M, Matsumoto Y, Takenaka Y, Iguchi K, Yamori T. New Marine Diterpenoids from the Okinawan Soft Coral *Clavularia koellikeri*. *J Nat Prod.* 2002;65(10):1441-1446.
120. Inoue A, Yoshida N, Omoto Y, Oguchi S, Yamori T, Kiyama R, Hayashi S. Development of cDNA microarray for expression profiling of estrogen-responsive genes. *J Mol Endocrinol.* 2002;29(2):175-192.
121. Iguchi K, Sawai H, Nishimura H, Fujita M, Yamori T. New Dolabellane-Type Diterpenoids from the Okinawan Soft Coral of the Genus *Clavularia*. *Bull Chem Soc Jpn.* 2002;75(1):131-136.
122. Hashimoto S, Xu Y, Masuda Y, Aiuchi T, Nakajo S, Uehara Y, Shibuya M, Yamori T, Nakaya K. β -Hydroxyisovalerylshikonin Is a Novel and Potent Inhibitor of Protein

Tyrosine Kinases. *Jpn J Cancer Res.* 2002;93(8):944-951.

123. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. *Cancer Res.* 2002;62(4):1139-1147.

124. Su W, Ito T, Oyama T, Kitagawa T, Yamori T, Fujiwara H, Matsuda H. The Direct Effect of IL-12 on Tumor Cells: IL-12 Acts Directly on Tumor Cells to Activate NF-kappaB and Enhance IFN-gamma-Mediated STAT1 Phosphorylation. *Biochem Biophys Res Commun.* 2001;280(2):503-512.

125. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by *s-p*-bromobenzylglutathione cyclopentyl diester in glyoxalase i-overexpressing human lung cancer cells. *Clin Cancer Res.* 2001;7(8):2513-2518.

126. Saji H, Koike M, Yamori T, Saji S, Seiki M, Matsushima K, Toi M. Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma. *Cancer.* 2001;92(5):1085-1091.

127. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson J, Hayashi S. Expression, Function, and Clinical Implications of the Estrogen Receptor beta in Human Lung Cancers. *Biochem Biophys Res Commun.* 2001;285(2):340-347.

128. Miyata F, Yoshida S, Yamori T, Katoh K. An efficient and expeditious synthesis of a novel 5H-naphth [1',2':5,6][1,4]oxazino[2,3-b]quinoxalin-5-one and its unique inhibitory activity against a panel of human cancer cell lines. *Heterocycles.* 2001;54(No. 2):619-622.

129. Komatsu Y, Tomizaki KY, Tsukamoto M, Kato T, Nishino N, Sato S, Yamori T, Tsuruo T, Furumai R, Yoshida M, Horinouchi S, Hayashi H. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. *Cancer Res.* 2001;61(11):4459-4466.

130. Iwasa K, Moriyasu M, Yamori T, Turuo T, Lee DU, Wiegrebe W. In vitro cytotoxicity of the protoberberine-type alkaloids. *J Nat Prod.* 2001;64(7):896-898.

131. Fukushima S, Takeuchi Y, Kishimoto S, Yamashita S, Uetsuki K, Shirakawa S, Suzuki M, Furuta K, Noyori R, Sasaki H, Kikuchi Y, Kita T, Yamori T, Sawada J, Kojima M, Hazato A, Kurozumi S, Fukushima M. Antitumor activity, optimum administration method and pharmacokinetics of 13,14-dihydro-15-deoxy-delta7 -prostaglandin A1 methyl ester (TEI-9826) integrated in lipid microspheres (Lipo TEI-9826). *Anticancer Drugs.* 2001;12(3):221-234.

132. Dan S, Yamori T. Repression of Cyclin B1 Expression after Treatment with Adriamycin, but Not Cisplatin in Human Lung Cancer A549 Cells. *Biochem Biophys Res*

Commun. 2001;280(3):861-867.

133. Oyama T, Miyoshi Y, Koyama K, Nakagawa H, Yamori T, Ito T, Matsuda H, Arakawa H, Nakamura Y. Isolation of a novel gene on 8p21.3-22 whose expression is reduced significantly in human colorectal cancers with liver metastasis. *Genes Chromosomes Cancer*. 2000;29(1):9-15.

134. Mimaki Y, Kuroda M, Sashiba Y, Yamori T, Tsuruo T. Candicanoside A, a Novel Cytotoxic Rearranged Cholestane Glycoside from *Galtonia candicans*. *Helv Chim Acta*. 2000;83(10):2698-2704.

135. Kuroda M, Mimaki Y, Sashida Y, Yamori T, Tsuruo T. Galtonioside A, a novel cytotoxic cholestane glycoside from *Galtonia candicans*. *Tetrahedron Lett*. 2000;41:251-255.

136. Hosokawa N, Inuma H, Takeuchi T, Sato S, Yamori T, Tsuchiya SK, Hori M. Anticancer and Some Biological Activities of Thiazinotrienomycin B. *J Antibiot*. 2000;53:306-308.

137. Egawa K, Yamori T, Nosaka C, Kunimoto S, Takeuchi T, Nos K. Deoxybomycin is a selective anti-tumor agent inducing apoptosis and inhibiting topoisomerase I. *Biol Pharm Bull*. 2000;23(9):1036-1040.

138. Akiyama N, Hijikata M, Kobayashi A, Yamori T, Tsuruo T, Natori S. Anti-tumor effect of N-beta-alanyl-5-S-glutathionyl-dihydroxyphenylalanine (5-S-GAD), a novel anti-bacterial substance from an insect. *Anticancer Res*. 2000;20(1a):357-362.

139. Yamori T, Matsunaga A, Sato S, Yamazaki K, Komi A, Ishizu K, Mita I, Edatsugi H, Matsuba Y, Takezawa K, Nakanishi O, Kohno H, Nakajima Y, Komatsu H, Andoh T, Tsuruo T. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. *Cancer Res*. 1999;59(16):4042-4049.

140. Naasani I, Seimiya H, Yamori T, Tsuruo T. FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. *Cancer Res*. 1999;59(16):4004-4011.

141. Iwasa K, Nishiyama Y, Ichimura M, Moriyasu M, Kim H-S, Wataya Y, Yamori T, Tsuruo T, Lee D-U. Structure-activity relationships of quaternary protoberberine alkaloids having an antimalarial activity. *Eur J Med Chem*. 1999;34:1077-1083.

142. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. *Oncogene*. 1999;18(3):813-822.

143. Hirai KI, Koyama J, Pan J, Simamura E, Shimada H, Yamori T, Sato S, Tagahara K, Tsuruo T. Furanonaphthoquinone analogs possessing preferential antitumor activity compared to normal cells. *Cancer Detect Prev*. 1999;23(6):539-550.

144. Chen Z, Naito M, Hori S, Mashima T, Yamori T, Tsuruo T. A human IAP-family

gene, apollon, expressed in human brain cancer cells. *Biochem Biophys Res Commun.* 1999;264(3):847-854.

145. Kawada M, Uehara Y, Mizuno S, Yamori T, Tsuruo T. Up-regulation of p27Kip1 correlates inversely with anchorage-independent growth of human cancer cell lines. *Jpn J Cancer Res.* 1998;89(2):110-115.

146. Yamori T, Sato S, Chikazawa H, Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. *Jpn J Cancer Res.* 1997;88(No. 12):1205-1210.

147. Numata A, Iritani M, Yamada T, Minoura K, Matsumura E, Yamori T, Tsuruo T. Novel antitumor metabolites produced by a fungal strain from a Sea Hare. *Tetrahedron Lett.* 1997;38(47):8215-8218.

148. Lim J, Kuroki T, Ozaki K, Kohsaki H, Yamori T, Tsuruo T, Nakamori S, Imaoka S, Endo M, Nakamura Y. Isolation of murine and human homologues of the fission-yeast *dis3+* gene encoding a mitotic-control protein and its overexpression in cancer cells with progressive phenotype. *Cancer Res.* 1997;57(5):921-925.

149. Fukuda S, Kuroki T, Kohsaki H, Hayashi S, Ozaki K, Yamori T, Tsuruo T, Nakamori S, Imaoka S, Nakamura Y. Isolation of a novel gene showing reduced expression in metastatic colorectal carcinoma cell lines and carcinomas. *Jpn J Cancer Res.* 1997;88:725-731.

150. Yamori T, Shimada K, Kanda H, Nishizuru Y, Komi A, Yamazaki K, Asanoma K, Ogawa M, Nomura K, Nemoto N, Kumada K, Tsuruo T. Establishment of a hepatocyte cell line producing growth-promoting factors for liver-colonizing tumor cells. *Jpn J Cancer Res.* 1996;87:146-152.

151. Satoh A, Takayama E, Kojima K, Ogawa H, Yamori T, Sato S, Kawaguchi T, Tsuruo T, Yoshimoto K, Kine T, Matsumoto I. Expression of Carbohydrate-binding protein p33/41 human tumor cell lines. *J Biochem.* 1996;119:346-353.

152. Ihara S, Nishikawa T, Kimura K, Fujiyoshi T, Shirai T, Komi A, Kanda H, Yamori T, Fukui Y. A novel differentiation factor for PC cells from culture supernatant of mouse hepatocyte cell line MLE-15A2. *Biosci Biotech Biochem.* 1996;60(8):1339-1345.

153. Ihara S, Iwamatsu A, Fujiyoshi T, Komi A, Yamori T, Fukui Y. Identification of interleukin-6 as a factor that induces neurite outgrowth by PC12 cells primed with NGF. *J Biochem.* 1996;120(5):865-868.

154. Toyoshima M, Nakajima M, Yamori T, Tsuruo T. Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. *Cancer Res.* 1995;55(4):767-773.

155. Matsushita Y, Yamamoto N, Shirahama H, Tanaka S, Yonezawa S, Yamori T, Irimura T, Sato E. Expression of sulfomucins in normal mucosae, colorectal

adenocarcinomas, and metastases. *Jpn J Cancer Res.* 1995;86:1060-1067.

156. Kawakami H, Kanai Y, Yamori T, Tsuruo T, Hirano H. Histochemical detection of sugar residues by joint of specific antibodies and lectins. *Acta Histochem Cytochem.* 1995;28(2):191-192.

157. Daduang S, Nagata S, Matsuda M, Yamori T, Onodera K, Fukui Y. Production of monoclonal antibodies specific to the carboxyl terminal region of the 85 kDa subunit of phosphatidylinositol 3-kinase: use of the antibodies in recognition of mutant p85. *Immunol Cell Biol.* 1995;73(2):134-139.

158. Tsuruo T, Inaba M, Tashiro T, Yamori T, Ohnishi Y, Ashizawa T, Sakai T, Kobayashi S, Gomi K. Evaluation of antitumor activity of navelbine (vinorelbine ditartrate) against human breast carcinoma xenografts based on its pharmacokinetics in nude mice. *Anticancer Drugs.* 1994;5:634-640.

159. Isoai A, Goto-Tsukamoto H, Yamori T, Oh-hara T, Tsuruo T, Silletti S, Raz A, Watanabe H, Akedo H, Kumagai H. Inhibitory effects of tumor invasion-inhibiting factor 2 and its conjugate on disseminating tumor cells. *Cancer Res.* 1994;54:1264-1270.

160. Furusaka A, Nishiyama M, Ohkawa K, Yamori T, Tsuruo T, Yonezawa K, Kasuga M, Hayashi S-i, Tanaka T. Expression of insulin receptor substrate-1 in hepatocytes: an investigation using monoclonal antibodies. *Cancer Lett.* 1994;84:85-92.

161. Yamanashi Y, Okada, M., Semba, T., Yamori, T., Umemori, H., Tsunasawa, S., Toyoshima, K., Kitamura, D., Watanabe, T. and Yamamoto, T. Identification of HS1 protein as major substrate of protein-tyrosine kinase(s) upon B-cell antigen receptor-mediated signaling. *Proc Natl Acad Sci USA.* 1993;90:3631-3635.

162. Kataoka S, Naito M, Fujita N, Ishii H, Ishii S, Yamori T, Nakajima M, Tsuruo T. Control of Apoptosis and Growth of Malignant T Lymphoma Cells by Lymph Node Stromal Cell. *Exp Cell Res.* 1993;207:271-276.

163. Inaba M, Sato S, Yamori T, Tashiro T, Ohnishi Y, Maruo K, Ueyama Y, Tsuruo T. Anticancer activities of orally administered menogaril against human stomach and breast cancers implanted in nude mice. *Anticancer Res.* 1992;12:1953-1956.

164. Yamori T, Iizuka Y, Takayama Y, Nishiya S, Iwashita S, Yamazaki A, Takatori T, Tsuruo T. Insulin-like growth factor I rapidly induces tyrosine phosphorylation of a Mr 150,000 and a Mr 160,000 protein in highly metastatic mouse colon carcinoma 26 NL-17 cells. *Cancer Res.* 1991;51:5859-5865.

165. Irimura T, Matsushita Y, Hoff SD, Yamori T, Nakamori S, Frazier ML, Giacco GG, Cleary KR, Ota DM. Ectopic expression of mucins in colorectal cancer metastasis. *Semin Cancer Biol.* 1991;2(2):129-139.

166. Yusa K, Sugimoto Y, Yamori T, Yamamoto T, Toyoshima K, Tsuruo T. Low

metastatic potential of clone from murine colon adenocarcinoma 26 increased by transfection of activated c-erbB-2 gene. *J Natl Cancer Inst.* 1990;82:1633-1636.

167. Tsuruo T, Saito H, Watanabe M, Sugimoto Y, Yamori T, Oh-hara T. Inhibition of lung colonization of mouse colon 26 adenocarcinoma by recombinant mouse interferon β through a modification of platelet function. *Clin Expl Metastasis.* 1990;8:203-213.

168. Yamori T, Ota DM, Cleary KR, Hoff S, Hager LG, Irimura T. Monoclonal antibody against human colonic sulfomucin: Immunochemical detection of its binding sites in colonic mucosa, colorectal primary carcinoma, and metastases. *Cancer Res.* 1989;49:887-894.

169. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin like growth factor I stimulate proliferation of metastatic variants of colon carcinoma 26. *Jpn J Cancer Res.* 1989;80:51-58.

170. Hoff SD, Matsushita Y, Ota DM, Cleary KR, Yamori T, Hakomori S, Irimura T. Increased expression of sialyl-dimeric LeX antigen in liver metastases of human colorectal carcinoma. *Cancer Res.* 1989;49(24 Pt 1):6883-6888.

171. Yamori T, Ota DM, Cleary KR, Irimura T. Increased content of chondroitin sulfate proteoglycan in human colorectal carcinoma metastases compared with the primary tumor as determined by an anti-chondroitin sulfate monoclonal antibody. *J Cellular Biochemistry.* 1988;36:405-416.

172. Yamori T, Iida H, Tsukagoshi S, Tsuruo T. Growth stimulating activity of lung extract on lung-colonizing colon 26 clones and its partial characterization. *Clin Expl Metastasis.* 1988;6:131-139.

173. Tsuruo T, Ishikawa T, Oh-hara T, Yamori T, Tsukagoshi S, Sugano H. Development of lymphosarcoma lines with high metastatic ability to lymph nodes and visceral organs in BALB/c mice. *Clin Expl Metastasis.* 1988;6:141-152.

174. Irimura T, Carlson DA, Yamori T, Giavazzi R, Ota DM, Cleary KR. Differential expression of a sialoglycoprotein with an approximate molecular weight of 900,000 on metastatic human colon carcinoma cells growing in culture and in tumor tissues. *Cancer Res.* 1988;48:2353-2360.

175. Yamori T, Kimura H, Stewart K, Ota DM, Cleary KR, Irimura T. Differential production of high molecular weight sulfated glycoproteins in normal colonic mucosa, primary colon carcinoma, and metastases. *Cancer Res.* 1987;47:2741-2747.

176. Sugimoto Y, Oh-hara T, Watanabe M, Saito H, Yamori T, Tsuruo T. Acquisition of metastatic ability in hybridomas between two low metastatic clones of colon adenocarcinoma 26 defective in either platelet-aggregating activity or *in vivo* growth potential. *Cancer Res.* 1987;47:4396-4401.

177. Irimura T, Yamori T, Bennett SC, Ota DM, Cleary KR. The relationship of collagenolytic activity to stage of human colorectal carcinoma. *Int J Cancer.* 1987;40:24-31.

178. Irimura T, Nakajima M, Yamori T, Ota DM, R. CK, Nicolson GL. Glycoconjugates and tumor metastasis. In: A. M. Wu (ed.), *Molecular Immunology of Complex Carbohydrates*. New York: Prentice-Hall Press. 1987;(□□):677-704.
179. Tsuruo T, Kawabata H, Iida H, Yamori T. Tumor induced platelet aggregation and growth promoting factors as determinants for successful tumor metastasis. *Clin Exp Metastasis*. 1986;4:25-33.
180. Tsuruo T, Iida H, Makishima F, Yamori T, Kawabata H, Tsukagoshi S, Sakurai Y. Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. *Cancer Chemother Pharmacol*. 1985;14:30-33.
181. Yamori T, Tsuruo T, Naganuma K, Tsukagoshi S, Sakurai Y. Isolation and characterization of highly and rarely metastatic clones from murine colon adenocarcinoma 26. *Invasion Metastasis*. 1984;4:84-97.
182. Tsuruo T, Yamori T, Naganuma K, Hori K, Kawabata H, Tsukagoshi S, Sakurai Y. Metastasis after intravenous inoculation of highly metastatic variant of mouse tumors and the effect of several antitumor drugs on the tumors. *Gann*. 1984;75:193-198.
183. Tsuruo T, Naganuma K, Yamori T, Kawabata H, Oh-hara T, Iida H, Tsukagoshi S, Sakurai Y. Spontaneous metastatic variants of mouse tumor and the effect of drugs on the metastasis. *Gann*. 1984;75:557-563.
184. Tsuruo T, Yamori T, Naganuma K, Tsukagoshi S, Sakurai Y. Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. *Cancer Res*. 1983;43:5437-5442.
185. Tsuruo T, Naganuma K, Iida H, Yamori T, Tsukagoshi S, Sakurai Y. Inhibition of lymph node metastasis of P388 leukemia by bestatin in mice. *J Antibiot (Tokyo)*. 1981;34:1206-1209.
186. Tsuruo T, Yamori T, Tsukagoshi S, Sakurai Y. Enhanced cytotoxic action of methotrexate by conjugation to concanavalin A. *Int J Cancer*. 1980;26:655-659.
187. Tsukagoshi S, Tsuruo T, Yamori T, Iida H, Naganuma K, Sakurai Y. Antitumor efficacy of aclacinomycin A. *J Pharmacokinetics*. 1980;3:532-536.